Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.



Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge

Screening: Cancer, Osteoporosis, and STDs

for Health Care Providers

Screening: Cancer, Osteoporosis, and STDs

Back to Chapter

Cervical cancer screening:
Abbreviations: ASCUS = atypical squamous cells of undetermined significance; CT = Chlamydia trachomatis; GC = Neisseria gonorrhea; HSIL = high-grade squamous intraepithelial lesion; LSIL = low-grade squamous intraepithelial lesion; NAAT = nucleic acid amplification test
  • Cervical Pap test (smear or liquid cytology)
  • Baseline
  • Repeat in 6 months
  • If both Pap results are normal and CD4 count is >200 cells/µL, repeat annually
  • If both Pap results are normal and CD4 count is <200 cells/µL, repeat every 6 months
  • If any Pap smear result is abnormal, additional testing should be done; see Cervical Dysplasia and Management of Abnormal Pap Smear Results, below
  • HIV-infected women are more likely than HIV-uninfected women to be infected with HPV, especially with oncogenic HPV types.
  • Dysplasia may involve the cervix, vulva, vagina, or anus.
  • Abnormalities on cervical colposcopy are seen in 64% of women with CD4 counts of <200 cells/µL and 34% of those with CD4 counts of >400 cells/µL.
  • HIV-infected women have decreased rates of clearance of HPV; as a result, they have an increased risk of disease progression and recurrence.
  • For management of abnormal results, see Cervical Dysplasia and Management of Abnormal Pap Smear Results, below.
Vulvar and vaginal cancer screening:
  • Visual and manual inspection
  • Evaluate at times of cervical Pap test
  • Suspicious lesions: colposcopy; biopsy
  • HIV-infected women have elevated rates of vulvar and vaginal neoplasia.
  • Lesions may be multifocal, extensive, and recurrent, and may have an unusual appearance; sometimes progressing rapidly, especially in women with CD4 counts of <200 cells/µL.
  • Apparent condylomata that are resistant to treatment and unusual vulvar lesions should be referred for biopsy; also check RPR.
Anal cancer screening:
  • Digital rectal examination (DRE)
  • Anal Pap test
No national guidelines for anal cancer screening; consider:
  • Baseline
  • Annual DRE and anal Pap screening if patient is sexually active and baseline result was normal
  • Use polyester swab and liquid cytology method, if available
  • Anal dysplasia and anal cancer rates among HIV-infected women are not fully known but appear to be higher than those for HIV-uninfected women.
  • Anal dysplasia is seen in women with and without a history of receptive anal sex.
  • ART has not been shown to prevent or alter the course of anal dysplasia.
  • ASCUS, LSIL, HSIL: Refer for high-resolution anoscopy with biopsy.
  • Screening was cost-effective in a small study; no large-scale clinical trials on cost-effectiveness have been conducted.
  • See Anal Dysplasia.
Breast cancer screening:
  • Mammogram
  • Age 40-69: every 1-2 years
  • Age ≥70: discuss and take into account estimated life expectancy and presence of comorbid disease
  • HIV-infected women do not appear to have elevated risk of breast cancer.
  • See Cancer Screening.
Osteoporosis/osteopenia screening:
  • Dual-energy X-ray absorptiometry (DEXA) bone densitometry
  • Baseline for patients at risk and all women >65 years of age
  • Also consider for thin female smokers >40 years of age
  • Every 1-2 years for patients with osteoporosis who are treated with bisphosphonates
  • Age and previous fracture are the most significant risk factors.
  • See Osteoporosis, below, for more information and treatment recommendations.
STD screening:
  • Cervical GC and CT (NAAT or culture of first-void urine or cervical specimen)
  • Rectal or pharyngeal testing for GC and CT, based on possible risks or exposures (NAAT or culture of swab)
  • Trichomonas (wet-mount examination or culture of vaginal secretions)
  • HBV, HCV
  • HSV IgG (type specific)
  • Perform at baseline, repeat according to risks or exposures (eg, every 3-6 months for women with new sex partners since previous examination)
  • STDs should be treated to prevent health complications for the patient, and also to prevent perinatal transmission or transmission to sex partners.
  • Inflammatory STDs may increase risk of HIV transmission to uninfected sex partners.
  • See Prevention for Positives.

From Women's Health
Primary Care of Veterans with HIV
Office of Clinical Public Health Programs
Veterans Health Administration, 2009